Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,313 shares of the biopharmaceutical company's stock after selling 19,185 shares during the period. Rafferty Asset Management LLC owned approximately 0.12% of Agios Pharmaceuticals worth $2,310,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $9,957,000. Paradigm Biocapital Advisors LP acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $9,084,000. Deutsche Bank AG lifted its position in Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares during the period. Finally, Casdin Capital LLC acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth approximately $8,215,000.

Agios Pharmaceuticals Stock Up 2.3%

Agios Pharmaceuticals stock opened at $29.84 on Tuesday. The company's fifty day simple moving average is $28.77 and its 200-day simple moving average is $36.47. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market cap of $1.73 billion, a P/E ratio of 2.63 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AGIO shares. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday. Finally, HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $56.00.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. The trade was a 4.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.